| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.028 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |